JAK2 p.Val617Phe (V617F) Mutation Status (Accredited)
Please note that from April 2024 this programme will be consolidated into the Myeloproliferative Neoplasms Diagnostic Testing programme (Click here) and is no longer available as a stand-alone programme.
Example JAK2 p.Val617Phe (V617F) Mutation Status Report
Annotated Trial JAK2 232401 v1.0.0 Repor[...]
Adobe Acrobat document [992.2 KB]
Annotated Trial JAK2 232401 v1.0.0 Repor[...]
Adobe Acrobat document [992.2 KB]
JAK2 p.Val617Phe (V617F) Mutation Status Performance Monitoring System
Performance Monitoring System for the JA[...]
Adobe Acrobat document [81.7 KB]
Performance Monitoring System for the JA[...]
Adobe Acrobat document [81.7 KB]
Print
Sitemap
Follow Us Online: Facebook Twitter LinkedIn Youtube
Available Links: Disclaimer | Privacy Policy | Cookie Policy (This website uses cookies)
Last updated 05/08/2025 © UK NEQAS for Leucocyte Immunophenotyping. Not to be reproduced in whole or part without permission.
UK NEQAS is a Company Limited by Guarantee (No.3012351) and a Registered UK Charity (No.1044013).